Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- First Subject Enrolled in US PII/III of Anti-MTBR Tau Antibody for Alzheimer’s: Eisai
January 20, 2022
- AnGes/Vasomune's COVID-19 Med Enters PIIa for Severe Hospitalized Patients in US
January 20, 2022
- SymBio Seeks to Start PII Trial for Pediatric Adenovirus Infections in UK
January 19, 2022
- Mitsubishi Tanabe Earns Japan Rights for ADC Zynlonta
January 19, 2022
- Ono, Neurimmune Extend Drug Discovery Pact for Neurodegenerative Diseases
January 18, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Nipro Grabs Rights for Nexium Authorized Generic, Filing Done in August
January 18, 2022
- Enhertu Accepted for FDA Review for Second-Line Breast Cancer Use
January 18, 2022
- MSD, Kyorin to Copromote Oral COVID-19 Med Lagevrio in Japan from Jan. 31
January 18, 2022
- CSL Behring Files Prophylactic Treatment for HAE Attacks in Japan
January 17, 2022
- Pfizer Files Oral COVID-19 Pill in Japan
January 14, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS
January 14, 2022
- Eisai “Strongly Opposes” Medicare Coverage Proposal for Aduhelm, Calls for Revisit
January 14, 2022
- Kitasato Institute, Sumitomo Dainippon’s KSP-1007 Enters US PI Study for Carbapenem-Resistant Bacterial Infections
January 14, 2022
- Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise
January 13, 2022
- Sawai to Launch E Keppra Granule Tablets on Feb. 1
January 13, 2022
- Daiichi Sankyo to Shutter Plexxikon to Maximize Investment in ADCs
January 13, 2022
- Ex-CMIC Exec Philippe Auvaro Joins Medical Data Vision
January 12, 2022
- Takeda Pushes Back Assumed Biosimilar Entry in US by 3-5 Years
January 12, 2022
- Takeda to Buy Adaptate to Bolster I/O Pipeline
January 12, 2022
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…